Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653570 | 1.00 | AKR1C3 (0.43) | AKR1C3AKR1C2LTB4RLTB4R2AOC3 | |
| SCHEMBL4969588 | 0.86 | AKR1C3 (0.52) | AKR1C3AKR1C2LTB4RLTB4R2 | |
| SCHEMBL4969599 | 0.86 | AKR1C3 (0.52) | AKR1C3AKR1C2LTB4RLTB4R2 | |
| SCHEMBL4970394 | 0.86 | AOC3 (0.52) | AOC3BCHENPC1RAB9A | |
| SCHEMBL4970387 | 0.86 | AOC3 (0.52) | AOC3BCHENPC1RAB9A | |
| SCHEMBL5654914 | 0.84 | KDM4E (0.55) | AKR1C3LTB4RLTB4R2APP | |
| SCHEMBL5654907 | 0.84 | KDM4E (0.55) | AKR1C3LTB4RLTB4R2APP | |
| SCHEMBL4970077 | 0.83 | FAAH (0.46) | AOC3FOLH1FAAHPTGS2RARB | |
| SCHEMBL4969846 | 0.83 | AOC3 (0.46) | LTB4R2AOC3FOLH1 | |
| SCHEMBL5654045 | 0.83 | AOC3 (0.46) | AOC3FOLH1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | AKR1C3 737/4885AKR1C2 671/4885LTB4R 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.